PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status.

Abstract	The novel agent PRIMA-1(met) can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1(met) as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1(met) may therefore act independently of MTp53 status and WTp53 transactivation.
Authors	Stéphane Supiot, Helen Zhao, Klas Wiman, Richard P Hill, Robert G Bristow
Journal	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Radiother Oncol) Vol. 86 Issue 3 Pg. 407-11 (Mar 2008) ISSN: 0167-8140 [Print] Ireland
PMID	18237796 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Aza Compounds Bridged Bicyclo Compounds, Heterocyclic Radiation-Sensitizing Agents Tumor Suppressor Protein p53 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one
Topics	Aza Compounds (pharmacology) Bridged Bicyclo Compounds, Heterocyclic (pharmacology) Cell Line, Tumor Humans Hypoxia Male Prostatic Neoplasms (drug therapy, radiotherapy) Radiation Tolerance (drug effects) Radiation-Sensitizing Agents (pharmacology) Tumor Suppressor Protein p53 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!